Amkor Technology Sets Pricing for $500 Million Senior Notes and Plans Redemption of 2027 Notes
September 9, 2025 - 08:52
TEMPE, Ariz., September 08, 2025—Amkor Technology has announced the pricing of $500 million in senior notes, which will carry an interest rate of 5.875% and are set to mature in 2033. This strategic move aims to bolster the company's financial position and support ongoing growth initiatives.
The company also revealed its intention to redeem existing senior notes that are due in 2027. This decision reflects Amkor's commitment to managing its debt effectively and optimizing its capital structure. By refinancing its obligations, the company aims to enhance its liquidity and reduce interest expenses.
The issuance of these new senior notes is expected to attract significant investor interest, given the favorable terms and the company's solid market position. As Amkor continues to navigate the dynamic semiconductor industry, these financial maneuvers are crucial for maintaining its competitive edge and ensuring long-term sustainability.
MORE NEWS
August 9, 2026 - 18:31
County agenda features tax, technology and fairgroundsThe meeting will center on how to fund the ongoing fairgrounds project, a long-discussed priority for the county. Officials are expected to review the latest cost estimates and possible revenue...
August 9, 2026 - 00:24
‘AI slop’ crackdown: LinkedIn, Snap target low-quality gen-AI contentSocial platforms are starting to push back against the flood of generic, machine-generated posts, but they are doing so carefully. LinkedIn and Snap have both announced new measures aimed at...
August 8, 2026 - 05:47
Why GigaCloud Technology (GCT) Is Up 21.7% After Strong Q2 Results And New Buyback PlanGigaCloud Technology saw its stock surge 21.7% in early trading following the release of its second-quarter financial results and the announcement of a new capital return program. The company...
August 7, 2026 - 22:40
As FDA Approves First-Ever mRNA Flu Vaccine For Older Adults, Past KFF Polling Showed Most In This Age Group Were Uncertain About the Technology’s SafetyOn August 5, 2026, the U.S. Food and Drug Administration gave the green light to the first messenger RNA flu vaccine for adults aged 50 and older. The decision came after a clinical trial involving...